The Industry Definitive Forum
for Actionable Insights
Systems biology is an interdisciplinary field that studies the complex interactions within the liver, other tissues and gut microbiota using a holistic approach. Detailed insights into the biological functions of the liver and its crosstalk with the gut microbiota can be used to develop novel strategies for the prevention and treatment of NASH, and facilitate more efficient drug development decisions.
This in-depth session focuses on:
Adil Mardinoglu, Assistant Professor of Systems Biology, Royal Institute of Technology (KTH)
Dr. Adil Mardinoglu is an expert in the field of Systems Biology and Bioinformatics. He received his Bachelor’s degree from Istanbul Technical University, Turkey in Electronic and Telecommunication Engineering and his Ph.D. from Waterford Institute of Technology, Ireland in drug targeting applications. He worked as a postdoctoral researcher at Trinity College Dublin, Ireland and Chalmers University of Technology, Gothenburg, Sweden. His recent research activities include the generation of the context specific genome-scale metabolic models for healthy human cell-types e.g. adipocytes, hepatocytes and myocytes as well as certain types of cancer e.g. liver cancer. He employed the reconstructed comprehensive models for revealing the molecular mechanisms of obesity associated diseases as well as for discovery of the novel biomarkers and drug targets. He also reconstructed personalized and population based models for liver cancer patients in order to identify anticancer drug targets that can inhibit the growth of, or kill tumors
Despite an arsenal of compounds ranging from early preclinical to late clinical development in NASH, challenges in diagnosing and stratifying patient populations hinder the ability to recruit and enrich patient cohorts in line with clinical trial demands.
From risk stratification, recruitment enrichment, treatment effect validation to how these come together as potential primary or secondary endpoints, be part of this constructive discussion around the main pillars of the NASH diagnostic conundrum.
Join your peers to discuss:
Dimitar Tonev, Honorary Consultant, HCV Research UK
Dimitar is a pharmaceutical physician with 20 years of drug and diagnostics development across the universe of chronic liver diseases. He acts as Medical Director for Humedics, Perspectum Diagnostics and has previously held the role of Medical Director at Promethera Biosciences and Regional Medical Director at Intercept Pharmaceuticals.